Oculus +27% as oral, throat infection products gain approval in Mexico

|About: Oculus Innovative Sciences,... (OCLS)|By:, SA News Editor

Oculus Innovative Sciences (OCLS +27%) says Mexican regulators approved its Microcyn60 Oral Care family of products intended for use as an adjunct treatment in mouth and throat infections.

OCLS says the commercialization of its Microcyn technology for the new indication lays the foundation for its introduction into other international markets, particularly Europe.

The first oral care product to be launched by OCLS' Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo.